X hits on this document

Word document

SAINT-PETERSBURG – 2010 - page 117 / 128

286 views

0 shares

0 downloads

0 comments

117 / 128

Petrova Natalia Nikolaevna – candidate of medical sciences, assistant-professor of the Department of Otolaryngology Herald Mechnikov Saint-Petersburg State Medical Academy, tel. 8(812)543-94-13, e-mail: mechnik@gmail.com

Material Received 20.05.2010 г.

1289 Сологуб+

UDC 616.988-08:616.36-002

© T.V. Sologub, M.G. Romantsov, N.A. Semenyako, S.N. Kovalenko, A.L. Kovalenko, D.S. Sukhanov, 2010

Sologub T.V.1, Romantsov M.G.1, Semenyako N.A.1, Kovalenko S.N.,2 Kovalenko A.L.2, Sukhanov D.S.1 Modern approach to HCV-infection treatment // Preventive and clinical medicine. – 2010. - № 2 (35). – Р.

1Saint-Petersburg state medical academy named after I. I. Mechnicov, Saint-Petersburg, Russia, 195067, Saint-Petersburg, Piskariovsky pr. 47, Tel.: 8(812)545-13-39, fax: 8(812)545-13-39. E-mail: mechnik@gmail.com

2Scientific-Technological Pharmaceutical Firm «POLYSAN», Russia, 191119, Saint-Petersburg, Ligovsky av., 112, tel.: 8(812)110-82-25,112-13-79, е-mail: sales@polysan.ru, STPF «POLYSAN», www.polysan.ru

Summary: Problems of viral hepatitis C immunopathogenesis are discussed. Special attention is paid to the increased Th1 cytokine production, providing active protection of the body against HCV. Modern approaches to therapy of chronic hepatitis C,  described in the literature, as well as own data of the authors including patient “thrice therapy” with the use of immunomodulators (cycloferon in a form of injections and tablets, galavit and derinat) of different mechanism of action, are presented. Comparative evaluation of the therapy efficiency is made. Cycloferon was shown to be the drug of choice on the background of viral hepatitis in drug addicts. Clinical-laboratory efficiency of remaxol - metabolic hepatoprotector with antioxidant  activity - is described. Its high efficiency in combination with good tolerance (side effects requiring discontinuation of the drug were registered in 0,3 % of cases) and minimum risk of the absence of biochemical remission allows to regard remaxol as a highly effective metabolic hepatoprotector for pathogenetic therapy of

Document info
Document views286
Page views286
Page last viewedSun Dec 04 04:52:58 UTC 2016
Pages128
Paragraphs1794
Words33610

Comments